Can a new drug combo outsmart Triple-Negative breast cancer?

NCT ID NCT06685796

NEW Completed Disease control Sponsor: BeBetter Med Inc Source: ClinicalTrials.gov ↗

First seen Aug 18, 2026 · Last updated Aug 18, 2026

Summary

This phase II trial is testing whether adding an experimental drug called BEBT-209 to standard chemotherapy (carboplatin and gemcitabine) can help people with advanced triple-negative breast cancer. The study will enroll about 65 women whose cancer has returned or spread and is not driven by hormones or HER2. The goal is to see if the combination can slow cancer progression and shrink tumors, while also checking safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BEBT-209 capsules combined with carboplatin and gemcitabine
What this could lead to: If successful, this combination could offer a new treatment option to slow the growth of advanced triple-negative breast cancer, potentially extending the time before the disease worsens.
What could go wrong: This is an early-stage (phase II) study with a small number of participants, so results may not be conclusive. The combination may cause side effects, and it is not yet known if it will be more effective than standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED TRIPLE-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED TRIPLE-NEGATIVE BREAST CANCER

Contacts and locations

Locations

Hunan Cancer Hospital

Changsha, Hunan, 410013, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, 510120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.